Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When effective anticancer therapies are, in fact, destabilizing the tumor's Group Phenotypic Composition.

NPJ precision oncology·2026
Same author

Evolutionary antifragile therapy is a treatment strategy to suppress drug resistance by exploiting dose response convexity.

Cancer research·2026
Same author

Mechanistic learning to predict and understand minimal residual disease.

bioRxiv : the preprint server for biology·2026
Same author

How Does Genetic Information Enable Life?

Bulletin of mathematical biology·2026
Same author

Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response.

Cancer research·2025
Same author

Polysialic Acid Presentation on Microporous Scaffolds Supports Neural Repair after Ischemic Stroke.

bioRxiv : the preprint server for biology·2025
Same journal

Future Directions for [18F]FDG PET in Central Nervous System Diseases.

PET clinics·2026
Same journal

How Fluorine-18-labeled Fluorodeoxyglucose PET Changed Clinical Practice in Central Nervous System Disorders.

PET clinics·2026
Same journal

<sup>18</sup>F-fluorodeoxyglucose PET in Major Psychiatric Disorders.

PET clinics·2026
Same journal

Five Decades of [18F]Fluorodeoxyglucose-PET in Neuropsychiatric Disorders: From Brain Metabolism to Precision Functional Imaging.

PET clinics·2026
Same journal

Brain [18F]FDG PET in Subjective Cognitive Complaints: From Diagnostic Gap to Neurobiological Insight.

PET clinics·2026
Same journal

FDG PET in Movement Disorders and Parkinsonian Syndromes.

PET clinics·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in

Kimberly Luddy1, Hannah Newman2, Jordan Gravon3

  • 1Department of Immunology, Cancer Biology and Evolution Program, Moffitt Cancer Center, Magnolia Drive, Tampa, FL, USA.

PET Clinics
|October 24, 2025
PubMed
Summary
This summary is machine-generated.

Metastatic prostate cancer resistance evolves via Darwinian selection. Evolution-informed strategies, like adaptive therapy, can delay resistance and improve outcomes by steering tumor growth.

Keywords:
Cancer evolutionImmunotherapyProstate cancerRadiopharmaceutical therapyTheranosticsevolutionary double bind

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.9K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

6.5K

Related Experiment Videos

Last Updated: Jan 14, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.9K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

6.5K

Area of Science:

  • Oncology
  • Evolutionary Biology
  • Cancer Treatment

Background:

  • Metastatic prostate cancer (mPCa) treatment faces challenges due to acquired drug resistance.
  • Continuous maximum tolerated dose (MTD) therapies can inadvertently drive tumor evolution and resistance via Darwinian selection.
  • Understanding tumor evolutionary dynamics is crucial for developing effective mPCa treatment strategies.

Purpose of the Study:

  • To review the critical role of evolutionary dynamics in metastatic prostate cancer treatment.
  • To highlight evolution-informed therapeutic strategies for delaying resistance.
  • To explore the potential of novel therapies like radiopharmaceutical therapy in combination with immunotherapy.

Main Methods:

  • Review of current literature on tumor evolution and cancer therapy.
  • Analysis of Darwinian selection principles in the context of mPCa.
  • Discussion of adaptive therapy and collateral sensitivity exploitation.
  • Exploration of radiopharmaceutical therapy and immunotherapy combinations.
  • Integration of mathematical modeling and computer simulations for treatment optimization.

Main Results:

  • Tumor resistance in mPCa is an evolutionary process driven by selection pressures.
  • Adaptive therapy and collateral sensitivity strategies can steer tumor evolution to delay resistance.
  • Radiopharmaceutical therapy, particularly with immunotherapy, shows promise for disseminated mPCa.
  • Mathematical models can optimize personalized, adaptive treatment regimens.

Conclusions:

  • Steering tumor evolution is key to overcoming resistance in metastatic prostate cancer.
  • Personalized, adaptive treatment regimens informed by evolutionary principles can improve patient outcomes.
  • Resistance can be transformed from a treatment failure into an exploitable vulnerability.